Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
celarivir potassium
- Development stage
- Phase 1
- Lead developer
- Ginkgo Tree Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Celarivir potassium (GT-0486) is a small molecule inhibitor of the hepatitis C virus (HCV) NS3/4A protease. Developed by Ginkgo Tree Pharmaceuticals (Suzhou), it was investigated for the treatment of chronic hepatitis C virus infection. The drug functions by binding to the active site of the NS3/4A serine protease, an enzyme complex essential for the proteolytic cleavage of the HCV polyprotein into mature non-structural proteins required for viral replication. Celarivir potassium underwent Phase 1 clinical evaluation in China to assess its safety, tolerability, and pharmacokinetics in healthy volunteers. Like other first- and second-generation protease inhibitors, it was designed to be part of a direct-acting antiviral (DAA) regimen to achieve sustained virologic response in patients with chronic HCV.
- Other names
- celarivir
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NSP3 (SARS-CoV-2 non-structural protein 3)NS4A (Hepatitis C virus NS4A)
Beyond the preview
Go deeper on celarivir potassium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on celarivir potassium.